Paper5115909
Mouse myeloma tumor stem cells: a primary cell culture assay.
Park CH and 2 others. J Natl Cancer Inst, 1971. Cited by 315 papers, by iCite.
Cite this record
ConductScience Library. Mouse myeloma tumor stem cells: a primary cell culture assay. Papers, record 5115909. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/5115909
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics17
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Cells | Major topic |
| Culture Techniques | Major topic |
| Mitosis | Major topic |
| Plasmacytoma | Major topic |
| Animals | |
| Cell Count | |
| Centrifugation | |
| Culture Media | |
| Hematopoietic Stem Cells | |
| Injections | |
| Karyotyping | |
| Kidney Tubules | |
| Methods | |
| Mice | |
| Mice, Inbred Strains | |
| Neoplasm Transplantation | |
| Spleen |
Source PubMed
Cited by116
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 315 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 39446925 | Epstein-Barr virus reactivation induces divergent abortive, reprogrammed, and host shutoff states by lytic progression. | PLoS Pathog | 2024 | https://conductscience.org/library/papers/39446925 | PubMed |
| 38965243 | Cancer stem cells: advances in knowledge and implications for cancer therapy. | Signal Transduct Target Ther | 2024 | https://conductscience.org/library/papers/38965243 | PubMed |
| 38915538 | Epstein-Barr virus reactivation induces divergent abortive, reprogrammed, and host shutoff states by lytic progression. | bioRxiv | 2024 | https://conductscience.org/library/papers/38915538 | PubMed |
| 37566052 | DCUN1D1 Is an Essential Regulator of Prostate Cancer Proliferation and Tumour Growth That Acts through Neddylation of Cullin 1, 3, 4A and 5 and Deregulation of Wnt/Catenin Pathway. | Cells | 2023 | https://conductscience.org/library/papers/37566052 | PubMed |
| 36648606 | Cancer Stem Cells are Actually Stem Cells with Disordered Differentiation: the Monophyletic Origin of Cancer. | Stem Cell Rev Rep | 2023 | https://conductscience.org/library/papers/36648606 | PubMed |
| 36338705 | Heterogeneity of glioblastoma stem cells in the context of the immune microenvironment and geospatial organization. | Front Oncol | 2022 | https://conductscience.org/library/papers/36338705 | PubMed |
| 35483929 | Human acute myeloid leukemia stem cells: evolution of concept. | Blood Res | 2022 | https://conductscience.org/library/papers/35483929 | PubMed |
| 34697469 | Analysis of clonogenic growth in vitro. | Nat Protoc | 2021 | https://conductscience.org/library/papers/34697469 | PubMed |
| 34693187 | From the niche to malignant hematopoiesis and back: reciprocal interactions between leukemia and the bone marrow microenvironment. | JBMR Plus | 2021 | https://conductscience.org/library/papers/34693187 | PubMed |
| 33959299 | Targeting Cancer Stem Cells-A Renewed Therapeutic Paradigm. | Oncol Hematol Rev | 2017 | https://conductscience.org/library/papers/33959299 | PubMed |
| 33644055 | A Mechanism Leading to Changes in Copy Number Variations Affected by Transcriptional Level Might Be Involved in Evolution, Embryonic Development, Senescence, and Oncogenesis Mediated by Retrotransposons. | Front Cell Dev Biol | 2021 | https://conductscience.org/library/papers/33644055 | PubMed |
| 32684928 | Clinical Impact of Breast Cancer Stem Cells in Metastatic Breast Cancer Patients. | J Oncol | 2020 | https://conductscience.org/library/papers/32684928 | PubMed |
| 32050631 | Multiple Myeloma: Available Therapies and Causes of Drug Resistance. | Cancers (Basel) | 2020 | https://conductscience.org/library/papers/32050631 | PubMed |
| 31700218 | Head and neck cancer management and cancer stem cells implication. | Saudi Dent J | 2019 | https://conductscience.org/library/papers/31700218 | PubMed |
| 31426611 | Cancer Stem Cells and Targeting Strategies. | Cells | 2019 | https://conductscience.org/library/papers/31426611 | PubMed |
| 30613312 | Cancer stem cell impact on clinical oncology. | World J Stem Cells | 2018 | https://conductscience.org/library/papers/30613312 | PubMed |
| 29133573 | The RARS-MAD1L1 Fusion Gene Induces Cancer Stem Cell-like Properties and Therapeutic Resistance in Nasopharyngeal Carcinoma. | Clin Cancer Res | 2018 | https://conductscience.org/library/papers/29133573 | PubMed |
| 28855316 | Stem/progenitor cells in pituitary organ homeostasis and tumourigenesis. | J Endocrinol | 2018 | https://conductscience.org/library/papers/28855316 | PubMed |
| 28624993 | Cancer stem cell marker glycosylation: Nature, function and significance. | Glycoconj J | 2017 | https://conductscience.org/library/papers/28624993 | PubMed |
| 28454446 | Lentivirus-mediated RNA interference of tripartite motif 68 inhibits the proliferation of colorectal cancer cell lines SW1116 and HCT116 in vitro. | Oncol Lett | 2017 | https://conductscience.org/library/papers/28454446 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/5115909
GET https://conductscience.org/api/papers/v1/5115909/cited_by?page=2